John W. Rogers Jr.
John W. Rogers Jr.'s purchase track record
How the stock did after each of John W. Rogers Jr.'s open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/10/2026 | RYAN | $264K | +13.8% | pending | — |
| 4/9/2026 | NKE | $173K | -1.9% | -20.3% | +13.8% |
| 12/27/2024 | NKE | $192K | -16.8% | -4.6% | +3.4% |
| 6/30/2022 | NKE | $1.03M | -6.5% | +15.5% | +1.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Ryan Specialty Faces Pricing Pressure Ahead of Q3 Earnings. Ryan Specialty Holdings is preparing to announce its third-quarter financial results on October 29, 2026. Recent reports indicate that pricing cycle pressures have weighed on the company's performance. This development is relevant as the stock trades near its 52-week low, with analysts maintaining a wide range of price targets.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Nike shares rise amid value interest and Foot Locker split. Nike stock rose 5% recently as investors focused on its value metrics, despite a lack of major corporate announcements. The company has also ended its partnership with Foot Locker, a move that may impact its retail shelf presence. While only 26% of analysts currently rate the stock a Buy, the average price target remains below the current trading range.
Transaction History
| NYT | ▲ Buy | Grant | 106 | $0 | 7/23/2026 | View on chart |
| RYAN | ▲ Buy | Open Market | 7,500 | $264K | 6/10/2026 | View on chart |
| RYAN | ▲ Buy | Grant | 5,757 | $0 | 4/28/2026 | View on chart |
| NYT | ▲ Buy | Grant | 2,277 | $0 | 4/22/2026 | View on chart |
| NYT | ▲ Buy | Grant | 88 | $0 | 4/16/2026 | View on chart |
| NKE | ▲ Buy | Open Market | 4,000 | $173K | 4/9/2026 | View on chart |
| NYT | ▲ Buy | Grant | 77 | $0 | 1/16/2026 | View on chart |
| NYT | ▲ Buy | Grant | 96 | $0 | 10/23/2025 | View on chart |
| NKE | ▲ Buy | Grant | 2,619 | $0 | 9/9/2025 | View on chart |
| NYT | ▲ Buy | Grant | 106 | $0 | 7/24/2025 | View on chart |
| RYAN | ▲ Buy | Grant | 2,323 | $0 | 5/30/2025 | View on chart |
| NYT | ▲ Buy | Grant | 3,589 | $0 | 4/30/2025 | View on chart |
| NYT | ▲ Buy | Grant | 100 | $0 | 4/17/2025 | View on chart |
| NYT | ▲ Buy | Grant | 65 | $0 | 1/23/2025 | View on chart |
| NKE | ▲ Buy | Open Market | 2,500 | $192K | 12/27/2024 | View on chart |
| NYT | ▲ Buy | Grant | 64 | $0 | 10/24/2024 | View on chart |
| NKE | ▲ Buy | Grant | 2,437 | $0 | 9/10/2024 | View on chart |
| NYT | ▲ Buy | Grant | 64 | $0 | 7/25/2024 | View on chart |
| RYAN | ▲ Buy | Grant | 2,496 | $0 | 4/30/2024 | View on chart |
| NYT | ▲ Buy | Grant | 4,048 | $0 | 4/24/2024 | View on chart |
| NYT | ▲ Buy | Grant | 73 | $0 | 4/18/2024 | View on chart |
| NYT | ▲ Buy | Grant | 53 | $0 | 1/18/2024 | View on chart |
| NYT | ▲ Buy | Grant | 62 | $0 | 10/26/2023 | View on chart |
| NKE | ▲ Buy | Grant | 1,981 | $0 | 9/12/2023 | View on chart |
| NYT | ▲ Buy | Grant | 62 | $0 | 7/27/2023 | View on chart |
| RYAN | ▲ Buy | Grant | 2,814 | $0 | 5/1/2023 | View on chart |
| NYT | ▲ Buy | Grant | 4,472 | $0 | 4/26/2023 | View on chart |
| NYT | ▲ Buy | Grant | 50 | $0 | 4/20/2023 | View on chart |
| NYT | ▲ Buy | Grant | 49 | $0 | 1/19/2023 | View on chart |
| NYT | ▲ Buy | Grant | 56 | $0 | 10/21/2022 | View on chart |
| NKE | ▲ Buy | Grant | 1,804 | $0 | 9/9/2022 | View on chart |
| NYT | ▲ Buy | Grant | 54 | $0 | 7/21/2022 | View on chart |
| NKE | ▲ Buy | Open Market | 10,000 | $1.0M | 6/30/2022 | View on chart |
| RYAN | ▲ Buy | Grant | 2,829 | $0 | 6/7/2022 | View on chart |
| NYT | ▲ Buy | Grant | 3,836 | $0 | 4/27/2022 | View on chart |
| NYT | ▲ Buy | Grant | 30 | $0 | 4/21/2022 | View on chart |
| RYAN | ▲ Buy | Grant | 4,361 | $0 | 3/18/2022 | View on chart |
| NYT | ▲ Buy | Grant | 23 | $0 | 1/20/2022 | View on chart |
| NYT | ▲ Buy | Grant | 17 | $0 | 10/22/2021 | View on chart |
| NKE | ▲ Buy | Grant | 1,206 | $0 | 10/6/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
NYT faces scrutiny over valuation and moat in recent analysis
Recent commentary questions whether The New York Times offers sufficient value compared to other legacy media stocks, noting concerns about its competitive advantage. This skepticism aligns with the stock trading near its 52-week low and below the average analyst target price. The discussion highlights the importance of assessing long-term earnings power in the current market environment.
NYT faces scrutiny over valuation and moat in recent analysis. Recent commentary questions whether The New York Times offers sufficient value compared to other legacy media stocks, noting concerns about its competitive advantage. This skepticism aligns with the stock trading near its 52-week low and below the average analyst target price. The discussion highlights the importance of assessing long-term earnings power in the current market environment.